Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M60.7Revenue $M--Net Margin (%)--Altman Z-Score-1.6
Enterprise Value $M42.1EPS $-0.8Operating Margin %--Piotroski F-Score4
P/E(ttm)--Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yY
Price/Book4.210-y EBITDA Growth Rate %-8.7Quick Ratio23.2Cash flow > EarningsY
Price/Sales--5-y EBITDA Growth Rate %1.0Current Ratio23.2Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-47.7Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-64.5Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M23.7ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with GALT

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
GALTGeorge Soros 2014-06-30 Sold Out -0.01%$10.23 - $14.81
($12.43)
$ 2.56-79%Sold Out0
GALTGeorge Soros 2014-03-31 Buy 0.01%$8.025 - $18.3
($14.02)
$ 2.56-82%New holding48,200
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

GALT is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


GALT: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
TRABER PETER GPresident & CEO 2015-06-01Buy4,000$2.531.19 view
FREEMAN KEVIN DDirector 2015-06-01Buy2,083$2.7-5.19 view
AMELIO GILBERT FDirector 2014-12-15Sell110$3.69-30.62 view
Greenberg ArthurDirector 2014-08-19Buy1,000$4.56-43.86 view
FREEMAN KEVIN DDirector 2014-08-15Buy1,000$4.7-45.53 view
CALLICUTT JACK WCFO 2014-08-14Buy1,000$4.55-43.74 view
TRABER PETER GPresident and CEO 2014-08-14Buy4,000$4.46-42.6 view
TRABER PETER GPresident and CEO 2014-08-13Buy1,000$4.42-42.08 view
Prelack StevenDirector 2014-04-11Sell6,000$11.84-78.38 view
Martin Rod DDirector 2014-01-13Sell100,000$14.84-82.75 view

Quarterly/Annual Reports about GALT:

News about GALT:

Articles On GuruFocus.com

More From Other Websites
Galectin Therapeutics Initiates Enrollment for GR-MD-02 Phase 2 Clinical Trial in NASH with... Jun 29 2015
Galectin Therapeutics Initiates Enrollment for GR-MD-02 Phase 2 Clinical Trial in NASH with... Jun 29 2015
Galectin Therapeutics Names Dr. Marc Rubin Lead Independent Director Jun 03 2015
Galectin Therapeutics to Present at LD Micro Invitational Conference Jun 03 2015
Galectin Therapeutics Names Dr. Marc Rubin Lead Independent Director Jun 03 2015
Galectin Therapeutics to Present at LD Micro Invitational Conference May 28 2015
Galectin Therapeutics to Present at LD Micro Invitational Conference May 28 2015
GALECTIN THERAPEUTICS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 27 2015
GALECTIN THERAPEUTICS INC Financials May 19 2015
Galectin Therapeutics to Webcast Corporate Update Following Annual Meeting of Stockholders May 15 2015
Galectin Therapeutics to Webcast Corporate Update Following Annual Meeting of Stockholders May 15 2015
Galectin Therapeutics Reports no Drug-Drug Interaction Between GR-MD-02 and Midazolam May 14 2015
GALECTIN THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... May 14 2015
Galectin Therapeutics Reports no Drug-Drug Interaction Between GR-MD-02 and Midazolam May 14 2015
Galectin Therapeutics Reports First Quarter 2015 Financial Results, Provides Business Update... May 11 2015
Galectin Therapeutics reports 1Q loss May 11 2015
Galectin Therapeutics reports 1Q loss May 11 2015
GALECTIN THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... May 11 2015
Galectin Therapeutics Reports First Quarter 2015 Financial Results, Provides Business Update... May 11 2015
GALECTIN THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report May 11 2015

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK